BiotechTube

Aducanumab + Placebo

Phase 2Terminated
0 watching 0 views this week⚡ Active
49
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Cognitive Dysfunction

Conditions

Cognitive Dysfunction, Alzheimer's Disease

Trial Timeline

Dec 20, 2018 → Jul 30, 2019

NCT ID
NCT03639987

About Aducanumab + Placebo

Aducanumab + Placebo is a phase 2 stage product being developed by Biogen for Cognitive Dysfunction. The current trial status is terminated. This product is registered under clinical trial identifier NCT03639987. Target conditions include Cognitive Dysfunction, Alzheimer's Disease.

Hype Score Breakdown

Clinical
17
Activity
12
Company
7
Novelty
5
Community
5

Clinical Trials (3)

NCT IDPhaseStatus
NCT05310071Phase 3Terminated
NCT03639987Phase 2Terminated
NCT02434718Phase 1Completed

Competing Products

20 competing products in Cognitive Dysfunction

See all competitors
ProductCompanyStageHype Score
Aricept (donepezil hydrochloride) + placeboEisaiApproved
85
DonepezilEisaiApproved
85
AriceptEisaiPhase 2
52
Donanemab + AducanumabEli LillyPhase 3
77
ABT-126 + PlaceboAbbViePhase 2
52
SDI-118 + PlaceboAbbViePhase 1
33
ABT-288 Low Dose + Placebo + ABT-288 High DoseAbbViePhase 2
52
AZD5213 + AZD5213 + AZD5213AstraZenecaPhase 2
52
MK-8931MerckPhase 1
33
Nicotine patch + MK-4334 + Placebo patch + Placebo capsuleMerckPhase 1
33
Verubecestat 12 mg (Parts 1 and 2) + Verubecestat 40 mg (Parts 1 and 2)MerckPhase 3
77
RivastigmineNovartisPhase 3
77
RivastigmineNovartisApproved
85
Exelon (rivastigmine) + PlaceboNovartisApproved
85
CanakinumabNovartisPhase 2
52
EvipleraGilead SciencesApproved
84
atorvastatinPfizerPre-clinical
22
bosutinibPfizerPhase 1
32
BIIB080 + BIIB080-matching placeboBiogenPhase 2
49
BIIB104BiogenPhase 2
49

Other Products from Biogen

Interferon-beta-1a + methylprednisoloneApproved
82
Dimethyl fumarateApproved
82
[18F]Florbetapir PET imagingApproved
82
dimethyl fumarateApproved
82
ibritumomab tiuxetan (Zevalin®)Approved
82